Table 1.
Baseline characteristics of the patients infected with SARS-CoV-2 while receiving a bDMARD
| Rheumatic disease, n (%) | |
| Juvenile idiopathic arthritis | 63 (55.8%) |
| Autoinflammatory diseases | 35 (30.9%) |
| Familial Mediterranean fever | 21 |
| Cryopyrin associated periodic syndrome | 5 |
| Hyperimmunoglobulin D syndrome | 4 |
| Chronic recurrent osteomyelitis | 3 |
| Idiopathic recurrent pericarditis | 1 |
| Pyogenic arthritis, pyoderma gangrenosum and acne syndrome | 1 |
| Vasculitis | 10 (8.9%) |
| Adenosine deaminase 2 deficiency | 4 |
| Takayasu arteritis | 3 |
| Polyarteritis nodosa | 1 |
| Other | 2 |
| Connective tissue diseases | 5 (4.4%) |
| Systemic lupus erythematosus | 3 |
| Sjögren’s disease | 1 |
| Juvenile dermatomyositis | 1 |
| Comorbidities, n (%) | 19 (16.8%) |
| Hypertension | 4 |
| Inflammatory bowel disease | 3 |
| Scoliosis | 3 |
| Chronic renal failure | 2 |
| Hereditary spherocytosis | 1 |
| Asthma | 1 |
| Cardiomyopathy | 1 |
| Adrenal insufficiency | 1 |
| Celiac disease | 1 |
| Growth hormone insufficiency | 1 |
| Hypothyroidism | |
| Disease-modifying antirheumatic drugs, n (%) | 42 (37.1%) |
| Methotrexate | 27 |
| Mycophenolate mofetil | 5 |
| Leflunomide | 4 |
| Azathioprine | 3 |
| Cyclosporine | 1 |
| Sulfasalazine | 1 |
| Hydroxychloroquine | 1 |